Literature DB >> 24382431

Staging, risk assessment and screening of breast cancer.

B Yalcin1.   

Abstract

Breast cancer is the most common female malignant disease in the western countries where a woman's lifetime risk of developing the disease is more than 10%. Nulliparity or use of hormonal replacement therapy, strong family history, or a history of therapeutic thoracic radiation are considerable high risk factors for the development of breast cancer. Nowadays more new effective therapeutic agents have been developed for the intervention of the breast cancer, but prognosis is still remained poor in the metastatic disease. For the general population, screening mammography in women older than 40-45 years has been shown to be effective in identifying early-stage breast cancer and in decreasing the mortality rate. In randomized screening mammography trials for breast cancer, it has been established that screening mammograms reduced breast cancer mortality in women older than 50 years of age by 25 to 30%. This review article summarizes the risk factors for developing breast cancer, methods for risk assessment and the accepted screening guidelines.

Entities:  

Mesh:

Year:  2013        PMID: 24382431

Source DB:  PubMed          Journal:  Exp Oncol        ISSN: 1812-9269


  8 in total

1.  Early-stage breast cancer is not associated with the risk of marital dissolution in a large prospective study of women.

Authors:  V S Laitala; T Saarto; E K Einiö; P Martikainen; K Silventoinen
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

Review 2.  Metastatic and triple-negative breast cancer: challenges and treatment options.

Authors:  Sumayah Al-Mahmood; Justin Sapiezynski; Olga B Garbuzenko; Tamara Minko
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  99mTc-Radiolabeled Silica Nanocarriers for Targeted Detection and Treatment of HER2-Positive Breast Cancer.

Authors:  Paolo Rainone; Antonella De Palma; Francesco Sudati; Valentina Roffia; Valentina Rigamonti; Lucia Salvioni; Miriam Colombo; Marilena Ripamonti; Antonello Enrico Spinelli; Davide Mazza; Pierluigi Mauri; Rosa Maria Moresco; Davide Prosperi; Sara Belloli
Journal:  Int J Nanomedicine       Date:  2021-03-08

4.  PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFβ Responses in Breast Cancer.

Authors:  Megan Agajanian; Anaamika Campeau; Malachia Hoover; Alexander Hou; Daniel Brambilla; Sa La Kim; Richard L Klemke; Jonathan A Kelber
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

5.  Selectivity of Pinus sylvestris extract and essential oil to estrogen-insensitive breast cancer cells Pinus sylvestris against cancer cells.

Authors:  Nguyen Thi Hoai; Ho Viet Duc; Do Thi Thao; Anne Orav; Ain Raal
Journal:  Pharmacogn Mag       Date:  2015-10       Impact factor: 1.085

6.  MiR-16-5p inhibits breast cancer by reducing AKT3 to restrain NF-κB pathway.

Authors:  Liwei Ruan; Xiaojun Qian
Journal:  Biosci Rep       Date:  2019-08-23       Impact factor: 3.976

7.  A five-miRNA panel in plasma was identified for breast cancer diagnosis.

Authors:  Minghui Li; Xuan Zou; Tiansong Xia; Tongshan Wang; Ping Liu; Xin Zhou; Shui Wang; Wei Zhu
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

8.  Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India.

Authors:  Nidhi Gupta; Rohan Kumar Verma; Sudeep Gupta; Shankar Prinja
Journal:  JCO Glob Oncol       Date:  2020-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.